Klebsiella and extended spectrum β-lactamases

International Journal of Antimicrobial Agents

Volumn 8, Issue 1, 1997, Pages 37-43

  Urban, Carl ^a,b   Rahal, James J ^a,b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cephalosporin resistance; extended spectrum lactamase; imipenem resistance; Klebsiella pneumoniae; plasmid mediated

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BACTERIAL ENZYME; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIUM ISOLATION; DRUG USE; EPIDEMIOLOGY; GENE EXPRESSION; HUMAN; HYDROLYSIS; KLEBSIELLA PNEUMONIAE; NONHUMAN; PLASMID; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 0030932917     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(96)00355-X     Document Type: Article

References (64)

1. Payne DJ, Marriott MS, Amyes SGB. Characterisation of a unique ceftazidime hydrolysing β-lactamase, TEM-E2. J Med Microb 1990;32:131-134.
2. Knothe H. Shah P, Kremery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;11:315-317.
3. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalance and suscepibility patterns. Rev Infect Dis 1988;10:867-878.
4. Philippon A, Labia R, Jacoby GA. Extended spectrum beta-lactamases. Antimicrob Agents Chemother 1989;33:1131-1138.
5. Jacoby GA, Medieros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1991;35:1697-1704.
6. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure, 1995;39:1211-1233.
7. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-590.
8. Jacobson K, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended spectrum cephalosporins in Group I-β-lactamase producing organisms. Clin Infect Dis 1995;21:1107-1113.
9. Jacoby GA. Genetics of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 1994;13:(suppl)1:2-11.
10. Katsanis G, Jacoby G. The frequency of extended spectrum β-lactamases in isolates of Klebsiella pneumoniae. J Antimicrob Chemother 1992;29:345-346.
11. Jacoby GA, Sutton L. Properties of plasmids responsible for production of extended spectrum β-lactamases. Antimicrob Agents Chemother 1991;35:164-169.
12. Ambler RP. The structure of β-lactamases. Philos Trans R Soc London Ser B 1980;289:321-331.
13. Knox JR. Extended-spectrum and inhibitor-resistant TEM-type β-lactamases; specificity, and three dimensional structure. Antimicrob Agents Chemother 1995;39:2593-2601.
14. DuBois Sk, Marriott MS, Amyes SGB. TEM-and SHV-derived extended-spectrum β-lactamases: relationship between selection, structure and function. J Antimicrob Chemother 1995;35:7-22.
15. Bauernfeind A, Chong Y, Schweighart S. Extended β-lactamase in Klebsiella pneumoniae including resistance to cephamycins. Infection 1989;17:316-321.
16. Papanicolaou GA, Mederiros AA, Jacoby GA. Novel plasmid-mediated β-lactamase (MIR-1) conferring resistance to oxyimino-and α-methoxy-β-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1990;34:2200-2209.
17. Bauernfeind A, Stemplinger I, Jungwirth R, Giamarellou H. Characterization of the plasmidic β-lactamase CMY-2 which is responsible for cephamycin resistance. Antimicrob Agents Chemother 1996;40:221-224.
18. Gazouli M, Tzouvelekis LS, Prinarakis E, Miriagou V, Tzelepi E. Transferable cefoxitin resistance in enterobacteria from greek hospitals and characterization of plasmid-mediated group 1 β-lactamase (LAT-2). Antimicrob Agents Chemother 1996;40:1736-1740.
19. Lemozy J, Sirot D, Chanal C, et. al. First characterization of inhibitor-resistant TEM (IRT) β-lactamases in Klebsiella pneumoniae strains. Antimicrob Agents Chemother 1995;33:2580-2582.
20. Nikaido H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989;33:1831-1836.
21. Pangon B, Bizet C, Bure A, et al. In vivo selection of a cephamycin-resistant porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 β-lactamase. J Infect Dis 1989;159:1005-1006.
22. Rice LB. Carias LL, Etter L, Shlaes DM. Resistance to cefoperazone-sulbactam in Klebsiella pneumoniae. Evidence for enhanced resistance resulting from coexistence of two different resistance mechanisms. Antimicrob Agents Chemother 1993;37:1061-1064.
23. Martinez-Martinez L, Hernandez-Alles S, Alberti S, Tomas JM, Benedi VJ, Jacoby GA. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum cephalosporins. Antimicrob Agents Chemother 1996;40:342-348.
24. imp, among clinically isolated strains of Serratia marcescens. Antimicrob Agents Chemother 1995;39:824-829.
25. Livingstone D, Gill MJ, Wise R. Mechanisms of resistance to the carbapenems. J Antimicrob Chemother 1995;35:1-5.
26. Bradford PA, Urban C, Mariano N, Rahal JJ, Bush K. Imipenem resistance in clinical isolates of Klebsiella pneumoniae results from ACT-1, a plasmid mediated AMP-C β-lactamase combined with loss of an outer membrane porin protein. Abstract C 31, 36th Interscience Conf Antimicrob Chemother. New Orleans, LA, 1996.
27. Ahmad M, Urban C, Mariano N, et al. Molecular epidemiology of imipenem resistant Klebsiella pneumonia. Abstr 34th Infect Dis Soc Am. New Orleans, LA, 1996.
28. Yokochi T, Inove Y, Jiang GZ, et al. Increased phosphodiesters in lipopolysaccharide prepared from the polymyxin β-resistant isolate of Klebsiella pneumoniae. Microbiol Immunol 1994;38:901-903
29. Rice LB, Willey SH, Papanicolaoe GA et al. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990;34:2193-2199.
30. Naumovski L, Quinn JP, Miyashiro D, et. al. Outbreak of ceftazidime resistance due to a novel extended-spectrum β-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992;36:1991-1996.
31. Meyer KS, Urban C, Eagan J, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late generation cephalosporins. Ann Intern Med 1993;119:353-358.
32. Rice LB, Eckstein EC, DeVente J, Shlaes DM Ceftazidime-resistant Klebsiellla pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996;23:118-124.
33. Urban C, Meyer KS, Mariano N, et al. Identification of TEM-26 β-lactamase responsible for a major outbreak of ceftazidime resistasnt Klebsiella pneumoniae. Antimicrob Agents Chemother 1994;38:392-395.
34. Katsanis GP, Spargo J, Ferraro MJ, Sutton L, Jacoby GA. Detection of Klebsiella pneumonia? and Escherichica coli strains producing extended spectrum β-lactamases. J Clin Microb 1994;32:691-696.
35. Brown DFJ, Wattam A, Walpole E. Detection of extended spectrum β-lactamases (ESBLs) with the E Test strip. Abstr D 12, 35th Interscience Conf Antimicrob Agents Chemother. San Francisco, CA, 1995.
36. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility test. National committee for clinical laboratory standards, Villanova, PA 1995;M100-S6 Vol. 15 No. 14.
37. Burwen DR, Banerjee SN, Gaynes RP and The National Nosocomial Infection Surveillance System. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis 1994;170:1622-1625.
38. Rice LB, Carias LL, Bonomo RA, Shlaes DM. Molecular genetics of resistance to both ceftazidime and β-lactam-β-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to β-lactam therapy. J Infect Dis 1996;173:151-158.
39. Jacoby GA, Han P, Alvarez M, Tenover F. Survey of extended-spectrum β-lactamase Abstr C 20, 35th Interscience Conf Antimicrob Agents Chemother. San Francisco, CA, 1995.
40. Jones RN, Kehrberg E, Erwin ME, Sader H. Epidemiologic studies of emerging antimicrobial resistance in USA hospitals: Report from a forty medical center surveillance of parenteral drug septibility. Abstr C 42, 34th Interscience Conf Antimicrob Agents Chemother. Orlando, Fla. 1994.
41. Venezia RA, Scarano FJ, Preston KE, et al. Molecular epidemiology of an SHV-5 extended-spectrum β-lactamase in enterobacteriacea isolated from infants in a neonatal intensive care unit. Clin Infect Dis 1995;21:915-923.
42. Sirot DL, Goldstein FW, Soussy CJ, et al. Resistance to cefotaxime and seven other β-lactams in members of the family Enterobacteriaceae: a three year study in France. Antimicrob Agents Chemother 1992;36:1677-1681.
43. Soilleux MJ, Morand AM, Arlett GJ, Scavizzi MR, Labia R. Survey of Klebsiella pneumoniae producing extended spectrum β-lactamases: prevalence of TEM-3 and first identification of TEM-26 in France. Antimicrob Agents Chemother 1996;40:1027-1029.
44. Legakis NJ, Maniatis A, Tzouvelekis LS. Prevalent mechanisms of resistance amoung common enterobacterial isolates in Greek hospitals. Microb Drug Resist 1995;1:331-333.
45. Lucet JC, Cheuret S, Ducre D, et al: Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996;22:430-436.
46. Chanal CM, Sirot DL, Petet A, et al. Multiplicity of TEM-derived β-lactamases from Klebsiella pneumoniae strains isolated at the same hospital and relationships between the responsible plasmids. Antimicrob Agents Chemother 1989;33:1915-1920.
47. Bingen EH, Desjaroins P, Arlet G, et al. Molecular Epidemiology of plasmid spread among extended broad-spectrum β-lactamase producing Klebsiella pneumoniae isolates in a pediatric hospital. Antimicrob Agents Chemother 1993;31:179-184.
48. Nouvellon M, Pons JL, Sirot D, Combe ML, Lemelamd JF. Clonal outbreaks of extended spectrum β-lactamases-producing strains of Klebsiella pneumoniae demonstrated by antibiotic susceptibility testing, β-lactamase typing and multilocus enzyme electrophoresis. J Clin Microbiol 1994;32:2625-2627.
49. Bradford PA, Urban C, Jaiswal A, et al. SHV-7, a novel cefotaxime-hydrolyzing β-lactamase, identified in Escherichica coli isolates from hospital nursing patients. Antimicrob Agents Chemother 1995;39:899-905.
50. Wiener J, Quinn J, Nathan C, et al. Molecular epidemiology of plasmid-mediated ceftazidime resistance in E. coli and Klebsiella pneumoniae in common with nursing homes. Abstr C 441, 34th Interscience Conf Antimicrob Agents Chemother. Orlando, FL, 1994.
51. Morosini MI, Canton R, Martinez-Beltran J, et al. New extended-spectrum TEM-type β-lactamase from Salmonella enterica subsp. enterica isolates in a nosocomial outbreak. Antimicrob Agents Chemother 1995;39:458-461.
52. Jett BC, Ritchie DJ, Reicheley R, Bailey TC, and Sahm DF. In vitro activities of various β-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins. Antimicrob Agents Chemother 1995;39:1187-1190.
53. Urban C, Mariano N, Mosinka-Snipas K, Jaiswal A, Spinucci C, Rahal JJ. In vitro evaluation of antimicrobial agents against ceftazidime resistant Klebsiella pneumoniae. Abstr 57, 34th Interscience Conf Antimicrob Agents Chemother. Orlando, FL, 1994.
54. Livermore DM. β-lactamase in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-584.
55. Rice LB, Carias LL, Shlaes DM. In vivo efficacies of β-lactam β-lactamase inhibitor combinations against a TEM-26 producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1994;38:2663-2664.
56. Cohen ML. Epidemiology of drug resistance:implications for a post antimicrobial era. Science 1992;257:1050-1055.
57. Hibbert-Rogers LCF, Heritage J, Gascoyne-Binzi DM., et al. Molecular epidemiology of ceftazidime resistant enterobacteriace from patients on a pediatric ward. J Antimicrob Chemother 1995;36:65-82.
58. Payne DJ, Cramp R, Winstanlely DJ, Knowles DJ. Comparative activities of clavulanic acid, sulbactam and tazobactam against clinically important enzymes. Antimicrob Agents Chemother 1994;38:767-772.
59. French GL, Shannon KP, Simmons N. Hospital outbreak of Klebsiella pneumoniae resistant to broad spectrum cephalosporins and β-lactam β-lactamase inhibitor combinations by hyperproduction of SHV-5 β-lactamase. J Clin Microbiol 1996;34:358-363.
60. Billstein SA. How the pharmaceutical industry brings an antibiotic drug to market in the United States. Antimicrob Agents Chemother 1994;38:2679-2682.
61. Tenover FC, Hughes JM. The challenges of emerging infectious diseases: development and spread of multiply-resistant bacteriol pathogens. JAMA 1996;275:300-304.
62. [62) LeDuc JW. World Health Organization strategy for emerging infectious diseases. JAMA 1996;175:318-320.
63. Berkelman RL, Pinner RW, Hughes JM. Addressing emerging microbial threats in the United Stales. JAMA 1996;275:315-317.
64. Payne DJ, Amyes SGB. Transferable resistance to extended-spectrum β-lactams: a major threat or minor inconvenience? J Antimicrob Chemother 1991;27:255-261.